PO-0963: Thulium-170 for Brachytherapy  by Shani, G.
S368  2nd ESTRO Forum 2013 
GYN GEC – ESTRO Recommendations for MR Image Based 
Brachytherapy. 
Results: Dosimetric outcome: The mean + SD HR-CTV was 45.2 +15.8 
cc and 42.5 + 19.5 cc for RD and PD experience respectively. The 
mean + SD point A dose was 73.4+4.5 Gy in RD experience Vs 93 + 24.8 
Gy with PD experience. Similarly,the mean + SD D90 doses were 70.9 + 
10.6 Gy for RD Vs 87.2 +4.4 Gy for PD data. For OAR's, the mean + SD 
ICRU rectal and bladder points were 63.5 + 8.1 and 80.4 + 34.4 Gy 
respectively. The D2cc for rectum, bladder and sigmoid for RD data 
were 57.8 + 7.7 Gy, 93.4 +24.6 Gy and 74.6 + 19.6 Gy while it was 64 + 
5.5 Gy, 74.8 +7.1 Gy and 65.2 + 5.4 Gy respectively for PD set.  
Clinical Outcome: For RD experience, with a median follow-up of 24 
months, 3 patients had local failure, 1 had right external iliac nodal 
failure, and 1 left supraclavicular nodal failure whereas for PD 
experience with a median follow-up of 16 months, 3 had local 
recurrence,1 nodal, 4: loco-regional + distant and 3 patients had 
distant failures. All the local recurrences in both the RD and PD 
experience were HR-CTV infield relapses. In RD experience, 1 patient 
had Grade ¾ procto-sigmoiditis (Sigmoid 2cc : 140 Gy ) whereas so far 
no patient has been reported with significant late toxicity in PD 
experience. 
Conclusions: There is an overall significant improvement in 
therapeutic ratio in favour of PD experience. With the HR-CTV 
volumes being the same, the target volume doses are higher, doses to 
sigmoid and bladder are lower. The clinical outcome looks promising 
in terms of local control rates, however, longer follow-up is required 
to assess late sequelae. 
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Purpose/Objective: Three dimensional image-guided brachytherapy 
allows the assessment of the dose to organs at risk with Dose Volume 
Histograms (DVHs). The purpose of this study was to find a correlation 
between the DVHs and in-vivo dosimetry measurements for the 
bladder and rectum. 
Materials and Methods: During the period from 2009 to 2011, a total 
of 17 cervix carcinoma patients were treated with High Dose Rate 
brachytherapy (Ir-192). After the implantation of the catheter and 
previous to the treatment, the patients were CT scanned generating a 
total of 28 CT datasets. In-vivo dosimetry was performed 2 to 3 times 
on each patient using Thermo Luminescence Dosimeters of LiF (TLD-
100). The TLD rods were inserted in plastic tubes and separated with 
wires to facilitate their location on the CT scan. The tubes were 
introduced in urethral and rectal catheters inside the patient. The 
TLDs were calibrated every treatment day using the same Ir-192 
source that was used for the treatment. Protocols of annealing and 
read-out were followed to reduce uncertainties in dose measurements 
around brachytherapy sources. A retrospective study of these patients 
was performed after the acquisition of the brachytherapy dose 
planning system, OncentraR Brachy v4.0. The 28 CT datasets were 
imported in the dose planning system, the bladder and rectum 
delineated, a dose plan reproducing the received treatment was 
generated and the DVHs calculated. The minimum dose to 5cc, 2cc, 
1cc and 0.1cc tissue receiving the highest dose (D5cc, D2cc, D1cc and 
D0.1cc) was recorded and correlated to the maximum and average dose 
measured with the TLDs.  
Results: Statistically significant correlation (p<0.001) was found 
between the bladder volumetric doses (D5cc, D2cc, D1cc and D0.1cc) and 
the measured maximum and average dose. The correlation 
coefficients were 0.83, 0.85, 0.87 and 0.87 respectively for the 
maximum dose and 0.84, 0.86, 0.86 and 0.85 respectively for the 
average dose. For the rectal data no statistically significant 
correlation was found (p<0.3). The correlation coefficients were 0.39, 
0.39, 0.38, 0.34 respectively for the maximum dose and 0.15, 0.15, 
0.14, 0.13 respectively for the average dose. 
Conclusions: The significant correlation between the volumetric 
bladder doses and the measurements indicate that in-vivo dosimetry is 
an important method of quality assurance and could be used as a 
complement to the 3D image-guided brachytherapy. The lack of 
correlation in the rectal data might be due to the length of the rectal 
catheter that reached the sigmoid area when it was fully inserted. 
Therefore the rectal measurements correspond to the sigmoid dose 
and not to the rectal dose. As a result of this study we started to use 
a shorter catheter to assure that the TLDs are located at the rectum.  
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Purpose/Objective: HDR brachytherapy is widely used for tumor 
treatment. The main disadvantage is that using Ir-192 requires heavily 
shielded treatment room with an expensive remote control room. The 
main purpose of this work is to develop a HDR brachytherapy source 
that can be used in every regular hospital operation room without the 
need of very expensive treatment and control rooms.We have found 
Tm-170 to be a suitable isotope for that purpose. We have 
manufactured many Tm-170 seeds and we present here the results of 
animal experiments and dosimetry of those Tm-170 sources.  
Materials and Methods: Thulium-170 (Tm-170) is a radioactive isotope 
of half-life128 days, emitting photons in the range of 7-84 keV (~11% 
of the radiation emitted) and two beta rays of energy E max = 880 keV 
24%, and E max = 970 keV 76%. Many Tm-170 seeds for the LDR 
treatment were made and one source for the HDR treatment. The LDR 
seeds were made of thulium rectangles of dimensions: 4 x 0.6 x 0.2 
mm or cylindrical of 0.6 mm diameter, 4 mm long. The thulium was 
inserted into titanium sealed tube of 0.8 mm od, 0.7 mm id and 7 mm 
long. LDR experiments were done with seed activity in the range 0.5-
2.5 mCi. The HDR source was made of thulium cylinder 0.6 diameter 5 
mm long inside a titanium tube, all in a stainless steel tube of 1.2 mm 
od, 1.0 mm id. It was activated to about 5 Ci. Dosimetry of the Tm 
170 sources was done using a number of different methods and was 
calculated with Monte Carlo codes. TLD and film dosimetry were done 
in a Perspex phantom, in the range 4 – 30 mm from the source center. 
Measurements with LUDLUM NaI(Tl) dosimeter were done in air. 80 
BALB/C mice carrying KHJJ tumor were used in the LDR experiments 
and 12 Lewis rats carrying CNS1 Rat brain tumor were used in the HDR 
experiments 
Results: Survival of the treated animals is as follows: 60% of the 
treated mice were fully cured compared to none of the control, 75% 
of the rats were fully cured compared to none of the control. 
Dosimetry yielded the following results: The average of the many dose 
measurements of both the LDR seeds and the HDR source at 1 cm from 
the source (seed) in a Perspex phantom was 236 cGy/h Ci. That is 
about 20 times smaller than the dose from Ir-192 source at 1 cm. 
When theTm-170 seed is wrapped with 0.1 mm thick gold foil, to 
remove the beta radiation, the photon dose at 1 cm is reduced by a 
factor of 2.  
Conclusions: The survival of the treated animals is very encouraging, 
in particular for the HDR experiments. As for the dosimetry, Tm-170 
yields a lower photon dose at 1 cm from the source than Ir-192, 
however, if the beta radiation is acceptable, than the dose in the 
range up to 3 mm from the source is higher for Tm-170 than for Ir-
192. To avoid hot spots near the source the beta can be partly remove 
by wrapping the source with a thin gold coat. The Tm-170 activity 
should be higher and the seeds can be implanted at distances smaller 
than 1 cm. The benefit of avoiding heavy shielding worth the effort. 
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Purpose/Objective: Robust and relevant quality control (QC) is 
essential to ensure accuracy and safety in radiotherapy. QC in HDR 
brachytherapy has not kept pace with clinical modernisation e.g. 
volume-based prescriptions and patient-specific inverse-optimisation. 
New QC standards are required to confirm dose distribution accuracy 
and avoid errors. Typical QC is currently limited to straight catheters, 
point doses and well chambers. A 'state of the art' practical 
implementation of advanced multichannel film dosimetry is presented 
to verify delivered dose distributions around treatment applicators 
and sources. 3 cases are presented; a cervix ring applicator, a 
shielded vaginal cylinder, and an isolated source catheter. The 
application of gamma assessment criteria in brachytherapy is 
discussed. 
Materials and Methods: A film-array water phantom was used to 
accurately position Gafchromic EBT3 film, cut to 12 x 12 cm. 
Multichannel film dosimetry separating dose-dependent and dose-
